LABS
BIOMATERIALS AND TE
CELL-INSTRUCTIVE MATERIALS
ORGANOTYPIC TISSUES
BIOMEDICAL DEVICES
LAB-ON-CHIP/ LAB-ON-DROP
NANOMEDICINE
SYNTHETIC BIOLOGY LAB
BIOROBOTICS LAB
ORGANOTYPIC TISSUES
Conventional cell culturing systems are constituted by rigid, bi-dimensional plates and flaskes, which totally fail to recapitulate the complexity of the natural cell microenvironment. Cell behavior observed in vitro might be a “beautiful artifact” that might not occur in vivo. This causes relevant problems when drawing out definitive conclusion on the in vivo effectiveness of some treatments or molecules, when the observation are based on 2D systems only. The activities of the organotypic tissue labs comprise tissue engineering processes aiming at the in vitro production of tissue and organ equivalents that fully mimic their in vivo counterparts. Novel tissue engineering strategies developed and implemented allowed to build-up viable and functional tissues like human skin, gut, lung and cervix.
The fabrication of such organ equivalents has important implications in the advancement of tissue-on-chip (TOC) technology. TOC aims at recapitulating the human physiology in a chip. TOC has been developed to enable the study of human physiology in a tissue-specific context, the development of in vitro models of diseases and to potentially provide a valid and effective replacement of animals in drug testing.
The in vitro fabrication of human organs also allows the development of damaged and/or pathologic tissues (i.e. wounded skin or tumoral tissues). This play a crucial role in the human health by providing living platform to study both new methods and therapies with the final aim to improve the quality of life.
The fabrication living tissue equivalents in vitro have high impact in the scientific context: to provide tissue on demand to biologists, doctors and engineers that are interested in the study of the human physiology in a tissue specific context.
Moreover, the implications in the industry and in the market are also high. The tissue equivalents, can serve as biological platform to screen cosmetic compound (€200B per year), drugs ($1200B per year), toxic chemicals (mor than 100k toxic agents) or used has advanced prosthesis to replace damaged parts (more than 3000 clinics, hospitals in Italy).